Science Explorer Back to mapMap

Most cited papers from Coherus BioSciences (United States)

What are the most cited papers from Coherus BioSciences (United States)?

The most cited paper from Coherus BioSciences (United States) is "Broad targeting of resistance to apoptosis in cancer" (Ramzi M. Mohammad et al., 2015), with 869 citations. Next come "Cancer prevention and therapy through the modulation of the tumor microenvironment" (393) and "IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity" (320).

Showing 50 of 59 papers. Every paper with more than 15 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Broad targeting of resistance to apoptosis in cancer Ramzi M. Mohammad et al. · Seminars in Cancer Biology Open access 28 Apr 2015 869
2 Cancer prevention and therapy through the modulation of the tumor microenvironment Stephanie C. Casey et al. · Seminars in Cancer Biology Open access 11 Apr 2015 393
3 IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity Martin Oft · Cancer Immunology Research Mar 2014 320
4 Designing a broad-spectrum integrative approach for cancer prevention and treatment Keith I. Block et al. · Seminars in Cancer Biology Open access180 authors 18 Nov 2015 302
5 PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients Aung Naing et al. · Cancer Cell Open access Nov 2018 256
6 Accurate RNA 3D structure prediction using a language model-based deep learning approach Tao Shen, Zhihang Hu, Siqi Sun et al. · Nature Methods Open access 21 Nov 2024 228
7 MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets Xintao Qiu et al. · Nature Communications Open access 13 May 2022 166
8 Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer Felix Yi-Chung Feng et al. · JAMA Oncology Open access 12 Feb 2021 156
9 Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells Ivan H. Chan et al. · Mucosal Immunology Open access 27 Nov 2013 144
10 Engineering Aptamer with Enhanced Affinity by Triple Helix-Based Terminal Fixation Lianhui Zhao, Xiaoyan Qi, Xiao-Chen Yan et al. · Journal of the American Chemical Society 14 Oct 2019 139
11 Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial Aung Naing et al. · The Lancet Oncology Open access 25 Sep 2019 120
12 Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes Adam Benjamin Weiner, Thiago Vidotto, Yang Liu et al. · Nature Communications Open access 10 Feb 2021 116
13 A multi-targeted approach to suppress tumor-promoting inflammation Abbas K. Samadi et al. · Seminars in Cancer Biology Open access 5 May 2015 111
14 A generative deep learning approach to de novo antibiotic design Aarti Krishnan et al. · Cell Open access 15 Aug 2025 92
15 TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells Jonathan Chou, Kai R. Trepka, Martin Sjöström et al. · European Urology Oncology Open access 22 Feb 2022 92
16 Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences Walter Rayford et al. · Communications Biology Open access 3 Jun 2021 87
17 Deep generative design of RNA aptamers using structural predictions Felix Wong, Dongchen He, Aarti Krishnan et al. · Nature Computational Science Open access 6 Nov 2024 83
18 Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors Harriet M. Kluger, J. Carl Barrett, Justin F. Gainor et al. · Journal for ImmunoTherapy of Cancer Open access Mar 2023 83
19 Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity Isabella C. Glitza et al. · Cancer Discovery Open access 3 Apr 2024 79
20 Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial Anis Amalina Abdul Hamid, Hsin-Chieh Huang, V. Wang et al. · Annals of Oncology Open access 12 Jun 2021 78
21 Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity Tracy C. Kuo, Amy Yen-Chi Chen, Ons Harrabi et al. · Journal of Hematology & Oncology Open access 30 Nov 2020 76
22 Disagreement on foundational principles of biological aging Vadim N. Gladyshev et al. · PNAS Nexus Open access 28 Nov 2024 63
23 Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials Paul Linh Nguyen et al. · International Journal of Radiation Oncology*Biology*Physics ReviewOpen access 31 Dec 2022 55
24 Pegylated IL ‐10 induces cancer immunity John Brian Mumm, Martin Oft · BioEssays Review 13 May 2013 53
25 Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars Kristof Vandekerckhove, Andreas Seidl, Hiten J. Gutka et al. · The AAPS Journal Open access 10 May 2018 47
26 Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics Karen A. Autio, Martin Oft · Current Oncology Reports Feb 2019 46
27 Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy J.A. Marascio et al. · Prostate Cancer and Prostatic Diseases Open access 12 Nov 2019 45
28 Rational Design of Liquid Formulations of Proteins Mark Cornell Manning, Jun Liu, Tiansheng Li et al. · Advances in protein chemistry and structural biology Book chapter 2018 41
29 Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer Felix Yi-Chung Feng, Shibu Thomas, Fred Saad et al. · JAMA Oncology Open access 3 Jun 2021 40
30 Mutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases Paul J. Sampognaro, Shruti Arya, Giselle M. Knudsen et al. · Molecular Neurodegeneration Open access 2 May 2023 38
31 The Potentiation of IFN-γ and Induction of Cytotoxic Proteins by Pegylated IL-10 in Human CD8 T Cells Ivan H. Chan, Victoria H. Wu, Melissa Bilardello et al. · Journal of Interferon & Cytokine Research 26 Aug 2015 37
32 Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells Narendiran Rajasekaran, Xiaoguang Wang, Sruthi Ravindranathan et al. · Cancer Immunology Immunotherapy Open access 24 Feb 2024 33
33 Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) Evaluation Richard Zang, Aline Barth, Harvey Wong et al. · Journal of Medicinal Chemistry 5 Jul 2022 32
34 Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens Zev A. Wainberg, Kynan Feeney, Myung Ah Lee et al. · BMC Cancer Open access 8 Jul 2020 32
35 Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs Francesca Civoli, Aparna Kasinath, Xiaoyan Cai et al. · The AAPS Journal 2 Dec 2019 31
36 Potential Anticancer Properties and Mechanisms of Action of Withanolides Abbas K. Samadi · ˜The œEnzymes Book chapter 2015 31
37 Neutralizing Antibody Validation Testing and Reporting Harmonization Heather A. Myler et al. · The AAPS Journal Open access 8 Jul 2023 30
38 Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab Andrea Necchi, Joep J. de Jong, Daniele Raggi et al. · European Urology 27 Mar 2021 29
39 Short-Acting Testosterone: More Physiologic? Gerwin Westfield, Ursula B. Kaiser, Dolores J. Lamb et al. · Frontiers in Endocrinology Open access 30 Sep 2020 28
40 An explainable deep learning platform for molecular discovery Felix Wong, Satotaka Omori, Alicia Li et al. · Nature Protocols 9 Dec 2024 27
41 A comparative study of PCS and PAM50 prostate cancer classification schemes Junhee Yoon, Minhyung Kim, Edwin Melencio Posadas et al. · Prostate Cancer and Prostatic Diseases Open access 2 Feb 2021 27
42 Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer Amar Upadhyaya Kishan et al. · European Urology Open access 23 May 2020 27
43 Risk‐Based Pharmacokinetic and Drug–Drug Interaction Characterization of Antibody–Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective Chunze Li, Rajeev M Menon, Markus Walles et al. · Clinical Pharmacology & Therapeutics 19 Oct 2021 25
44 Improved DNA Extraction and Amplification Strategy for 16S rRNA Gene Amplicon-Based Microbiome Studies Bo‐Young Hong, Mark D. Driscoll, Dawn Gratalo et al. · International Journal of Molecular Sciences Open access 4 Mar 2024 22
45 Isoform separation of proteins by mixed-mode chromatography Tsutomu Arakawa, Sean Ponce, Glen W. Young · Protein Expression and Purification 13 Aug 2015 22
46 High-resolution microbiome analysis reveals exclusionary Klebsiella species competition in preterm infants at risk for necrotizing enterocolitis Spencer Coleman, Katrin Unterhauser, Karim Rezaul et al. · Scientific Reports Open access 16 May 2023 21
47 Cancer research in the United States: A critical review of current status and proposal for alternative models Hagop M. Kantarjian, Ferran Prat, David P. Steensma et al. · Cancer Open access 14 May 2018 21
48 Statistical Approaches to Assess Biosimilarity from Analytical Data Richard K. Burdick, Todd S. Coffey, Hiten J. Gutka et al. · The AAPS Journal 5 Oct 2016 20
49 Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer Yuki Yoshikawa, Konrad Hermann Stopsack, Victoria Wang et al. · Molecular Oncology Open access 10 Sep 2022 19
50 The Selective Peroxisome Proliferator‐Activated Receptor Gamma Modulator CHS‐131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis Nikolaos Perakakis, Aditya Joshi, Natia Peradze et al. · Hepatology Communications Open access 28 Jul 2020 19

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.